Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.63 |
| ▸ | TERT | O14746 | 1/20 | 0.63 |
| ▸ | APAF1 | O14727 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26787128 | 0.79 | APP (0.57) | APPTERTAPAF1EGFRELANE | |
| SCHEMBL11443324 | 0.78 | APP (0.74) | APPTERTAPAF1EGFRPDE3B | |
| SCHEMBL5696512 | 0.78 | APP (0.74) | APPTERTAPAF1EGFRPDE3B | |
| Acridine Orange SCHEMBL29361720 | 0.78 | TERT (1.00) | APPTERTAPAF1EGFRELANE | |
| SCHEMBL8406004 | 0.78 | KDM4E (0.52) | APPTERTAPAF1PDE3BPDE3A | |
| Acridine Orange SCHEMBL297155 | 0.78 | TERT (1.00) | APPTERTAPAF1EGFRELANE | |
| SCHEMBL6123011 | 0.76 | APP (0.48) | APPTERTAPAF1EGFRELANE | |
| SCHEMBL5470833 | 0.76 | APP (0.48) | APPTERTAPAF1EGFRELANE | |
| SCHEMBL2672333 | 0.76 | MAPT (0.53) | APPTERTAPAF1EGFRELANE | |
| Hydrochloric Acid SCHEMBL11309013 | 0.76 | APP (0.49) | APPTERTAPAF1EGFRELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064710-A1 | NUCLEIC ACID MODIFYING REAGENTS AND USES THEREOF | PROMEGA CORPORATION | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064710-A1 | NUCLEIC ACID MODIFYING REAGENTS AND USES THEREOF | POLRMT, NSUN2, ADAR | APP 4685/4885TERT 306/4885APAF1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.